ReviewIrish journal of medical science2026
Subclinical inflammation and early pathogenesis of rheumatic diseases: mechanistic insights relevant to primary care.
Review in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rheumatic diseases exhibit insidious onset and non-specific early manifestations, causing substantial diagnostic delays in primary care. This delay is closely linked to a prolonged subclinical inflammation phase, where pathogenic immune processes are active yet clinically inapparent. The mechanistic basis of this early disease concealment remains incompletely synthesized. Subclinical inflammation represents a state of persistent, low-grade immune activation in the absence of overt clinical signs, structural damage, or marked laboratory abnormalities. This phase is driven primarily by innate immune priming, sterile inflammation, and low-intensity cytokine signaling, which together sustain immune dysregulation below conventional diagnostic thresholds. Key processes include pattern recognition receptor activation, inflammasome signaling, modest but chronic cytokine production, and gradual erosion of immune tolerance. These mechanisms precede adaptive immune engagement, autoantibody maturation, and tissue-specific inflammation, thereby creating a temporal dissociation between molecular pathology and clinical expression. Disease-specific evidence from rheumatoid arthritis and systemic lupus erythematosus how subclinical inflammation constitutes a common early pathogenic state across diverse rheumatic conditions. Importantly, the heterogeneity and compartmentalization of early immune activation explain why routine clinical assessment and standard inflammatory markers frequently fail to detect active disease in primary care. By integrating current mechanistic insights, this review reframes diagnostic delay as a biologically driven phenomenon rather than a limitation of clinical practice. Understanding the mechanisms of subclinical inflammation provides a rational framework for risk-informed recognition and timely referral in primary care, with potential implications for improving long-term outcomes in rheumatic diseases.
Indexed as
Identifiers
42804139What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.